Drugs News and Research

RSS

Ohio State University researchers first to observe real-time behavior of the Dpo4 enzyme

Scientists here have identified how the motions of an enzyme are related to correctly copying genetic instructions, setting the stage for studies that can uncover what happens when DNA copying mistakes are made.

28 Oct 2009

Bcl-2 inhibitor may enhance chemotherapy treatment in patients with prostate cancer

In trying to better predict a patient's response to chemotherapy for cancer treatment, a team of investigators at The Cancer Institute of New Jersey (CINJ) and Rutgers, The State University of New Jersey, has identified a way to better manipulate a gene product to cause cancer cells to die.

28 Oct 2009

NCI funds pilot study to measure human proteins

An expert in cancer proteomics at Fred Hutchinson Cancer Research Center has received $4.8 million in federal stimulus funding from the National Cancer Institute to co-lead a pilot study to assess the feasibility and scalability of a project that aims to measure all of the proteins in the human body.

28 Oct 2009

NCI grant to conduct innovative cancer research

A consortium led by The University of Texas Health Science Center at Houston has been awarded a major grant from the National Cancer Institute (NCI) to establish a center to conduct innovative cancer research.

28 Oct 2009

Scientists explore genetic 'Prozac markers'; research may provide simple test for treating depression

Prozac works wonders for some depressed people, but not for others. In some cases, patients derive little benefit and at worst, it can lead to bizarre hallucinations and fits of rage. Researchers and doctors remain puzzled as to what causes the wide range of reaction to Prozac and similar antidepressants.

28 Oct 2009

Isotechnika Pharma reports voclosporin Phase 2/3 clinical trial results at the AAO meeting

Isotechnika Pharma Inc. today announced that results of the international Phase 2/3 clinical trials studying voclosporin, conducted by its partner Lux Biosciences, were the subject of two podium presentations at the American Association of Ophthalmology (AAO) meeting and of a presentation at the satellite meeting of the American Uveitis Society (AUS) in San Francisco, October 24-27.

27 Oct 2009

Also in Global Health news: U.S. grant to Uganda; reproductive health in Philippines; counterfeit drugs

The U.S. Embassy in Uganda announced a grant of $246 million in new aid for improving the Uganda's agricultural and health systems, Reuters reports. "More than $170 million will be spent on health and education to combat the HIV/AIDS pandemic, fight tuberculosis, eradicate malaria, improve maternal and child health and increase access to family planning and reproductive health services," the news service writes (Biryabarema, 10/27).

27 Oct 2009

Medicare payment issues worry doctors

The issue of Medicare payment cuts to doctors still looms, causing some physicians to shun Medicare patients and others to push for greater reform. Many worry that doctors may boycott the program if the planned 21 percent cut in payment rates goes through in 2010 while others complain about low Medicare reimbursement rates for certain procedures and geographic areas.

27 Oct 2009

More people rely on alternative medicine

As consumers look to save money in a tough economy, many turn to alternative health care options. CBS 4 reports: "Health care costs are soaring. Thousands of people are without jobs and without the benefits afforded them. Now, those people are turning to preventative or alternative measures. ... The National Center for Complimentary and Alternative Medicine (NCCAM) shows 38 percent of adults and 12 percent of kids are now using alternative therapies to treat pain. In fact, Americans are now reportedly spending $34 billion a year on alternative therapies" (Demos, 10/26).

27 Oct 2009

Champions Biotechnology obtains global rights to Tel Aviv University's TAR-1 compound

Champions Biotechnology, Inc., an oncology drug development company with a predictive preclinical platform aimed at accelerating the development and enhancing the value of oncology drugs, has established an exclusive licensing agreement with Ramot at Tel Aviv University Ltd., Tel Aviv University's wholly owned technology transfer company.

27 Oct 2009

Positive results from Logical Therapeutics' Phase I/II LT-NS001 clinical study

Logical Therapeutics, Inc., a Waltham, MA-based biopharmaceutical company announced today the positive results of a Phase I/II clinical trial evaluating the gastrointestinal (GI) safety of its investigational drug LT-NS001, the first of a new class of bio-activated prodrugs being developed for the chronic treatment of arthritic conditions.

27 Oct 2009

New Trace Express Viewer software from CDC Software

CDC Software Corporation, a global provider of enterprise software applications and services, today announced the availability of Trace Express Viewer, a new solution for its Ross ERP Lot Trace application that enables easier use, faster access and immediate forward and backward trace functionality to identify suspect materials and assist in the disposition of finished goods in the event of a product recall - key functionalities for product safety and compliance.

27 Oct 2009

Study reveals that adding ezetimibe to atorvastatin aids in reducing cholesterol

Edmonton - Adding ezetimibe to atorvastatin significantly boosted the attainment of lipid targets as specified by both Canadian and European guidelines in elderly patients aged 65 and older and the combination produced superior results than simply increasing the dose of atorvastatin alone, Dr. Christian Constance told the Canadian Cardiovascular Congress 2009, co-hosted by the Heart and Stroke Foundation and the Canadian Cardiovascular Society.

27 Oct 2009

New anti-flu drugs to fight flu virus could become a reality

New anti-flu drugs could become a reality as a result of a study carried out by academics at the University of Hertfordshire.

27 Oct 2009

Adenosine deaminase enzyme therapy offers hope for priapism

For men coping with painful erections lasting for long periods of time, or priapism, new research published online in The FASEB Journal (http://www.fasebj.org) offers hope. That's because researchers from the United States and China show that the enzyme adenosine deaminase may prevent priapism from progressing to penile fibrosis, a condition associated with the build up of scar tissue and eventual impotence.

27 Oct 2009

USAID and USP join to combat substandard and counterfeit medicines

With substandard and counterfeit versions of medicines intended to treat life-threatening diseases such as malaria, HIV/AIDS and tuberculosis posing a growing threat throughout the developing world, the U.S. Agency for International Development (USAID) and the U.S. Pharmacopeial Convention (USP) will expand their joint efforts to combat this menace by launching a new program over the next five years.

27 Oct 2009

Fero Industries to complete acquisition of Pyro Pharmaceuticals by November 30, 2009

Fero Industries, Inc. is pleased to provide certain disclosures relating to the ten pending patent applications of Pyro Pharmaceuticals, Inc. As previously announced, the Company has initiated the process of acquiring Pyro Pharmaceuticals, Inc. through an exchange of Pyro’s capital stock for shares of the Company’s common stock, with Fero remaining as the parent entity and Pyro as a subsidiary. The acquisition of Pyro is expected to close by November 30, 2009.

27 Oct 2009

Hutchinson Center receives USAID grant to build a cancer clinic and medical-training facility in Africa

Building on the strengths of two institutions separated by nearly 9,000 miles over two continents - both renowned in their work in the fight against cancer - the United States Agency for International Development has awarded a $500,000 grant to Fred Hutchinson Cancer Research Center to aid in the construction of the first American cancer clinic and medical-training facility in Africa.

27 Oct 2009

LX211 may become the first approved oral treatment for modifying the course of uveitis

An experimental drug, LX211 (LUVENIQ - oral voclosporin), may become the first approved oral treatment capable of modifying the course of uveitis, a group of serious eye conditions inevitably associated with either severe vision loss or substantial morbidity from steroid use.

27 Oct 2009

FDA warns four companies to stop marketing illegal opioid pain relievers

The U.S. Food and Drug Administration today warned four companies that they must stop marketing unapproved codeine sulfate tablets. These drugs are opioid analgesics, commonly called narcotics, that are widely used to treat pain.

27 Oct 2009

Drugs News and Research

Ohio State University researchers first to observe real-time behavior of the Dpo4 enzyme

Bcl-2 inhibitor may enhance chemotherapy treatment in patients with prostate cancer

NCI funds pilot study to measure human proteins

NCI grant to conduct innovative cancer research

Scientists explore genetic 'Prozac markers'; research may provide simple test for treating depression

Isotechnika Pharma reports voclosporin Phase 2/3 clinical trial results at the AAO meeting

Also in Global Health news: U.S. grant to Uganda; reproductive health in Philippines; counterfeit drugs

Medicare payment issues worry doctors

More people rely on alternative medicine

Champions Biotechnology obtains global rights to Tel Aviv University's TAR-1 compound

Positive results from Logical Therapeutics' Phase I/II LT-NS001 clinical study

New Trace Express Viewer software from CDC Software

Study reveals that adding ezetimibe to atorvastatin aids in reducing cholesterol

New anti-flu drugs to fight flu virus could become a reality

Adenosine deaminase enzyme therapy offers hope for priapism

USAID and USP join to combat substandard and counterfeit medicines

Fero Industries to complete acquisition of Pyro Pharmaceuticals by November 30, 2009

Hutchinson Center receives USAID grant to build a cancer clinic and medical-training facility in Africa

LX211 may become the first approved oral treatment for modifying the course of uveitis

FDA warns four companies to stop marketing illegal opioid pain relievers

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Latest News